MX2019014687A - Oral pharmaceutical formulations of remogliflozin. - Google Patents
Oral pharmaceutical formulations of remogliflozin.Info
- Publication number
- MX2019014687A MX2019014687A MX2019014687A MX2019014687A MX2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A
- Authority
- MX
- Mexico
- Prior art keywords
- remogliflozin
- release layer
- pharmaceutically acceptable
- immediate release
- pharmaceutical formulations
- Prior art date
Links
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 title abstract 2
- 229940126844 remogliflozin Drugs 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 abstract 2
- 229950011516 remogliflozin etabonate Drugs 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una formulación oral de liberacion inmediata de remogliflozina o sales farmaceuticamente aceptables de la misma administrada en pacientes que la necesitan, para el tratamiento de la diabetes mellitus. La presente invencion se refiere ademas a una formulación farmacéutica que comprende una combinacion sinérgica de etabonato de remogliflozina y clorhidrato de metformina. En una modalidad preferida, la invencion se refiere a un comprimido bicapa que comprende una capa de liberacion inmediata y una capa de liberacion prolongada en donde la capa de liberacion inmediata comprende etabonato de remogliflozina o sus sales farmaceuticamente aceptables y la capa de liberacion prolongada comprende metformina o una sal farmaceuticamente aceptable de la misma.The present invention relates to an immediate release oral formulation of remogliflozin or pharmaceutically acceptable salts thereof administered to patients in need thereof, for the treatment of diabetes mellitus. The present invention further relates to a pharmaceutical formulation comprising a synergistic combination of remogliflozin etabonate and metformin hydrochloride. In a preferred embodiment, the invention relates to a bilayer tablet comprising an immediate release layer and a prolonged release layer wherein the immediate release layer comprises remogliflozin etabonate or its pharmaceutically acceptable salts and the prolonged release layer comprises metformin. or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721020166 | 2017-06-08 | ||
| PCT/IB2018/054091 WO2018198102A1 (en) | 2017-06-08 | 2018-06-07 | Oral pharmaceutical formulations of remogliflozin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014687A true MX2019014687A (en) | 2020-10-15 |
Family
ID=63919598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014687A MX2019014687A (en) | 2017-06-08 | 2018-06-07 | Oral pharmaceutical formulations of remogliflozin. |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20200013719A (en) |
| CN (1) | CN110753540A (en) |
| BR (1) | BR112019026029A2 (en) |
| MX (1) | MX2019014687A (en) |
| PH (1) | PH12019502767A1 (en) |
| WO (1) | WO2018198102A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019162841A1 (en) * | 2018-02-21 | 2019-08-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus |
| MX2020008546A (en) * | 2018-02-21 | 2021-01-08 | Glenmark Pharmaceuticals Ltd | Pharmacutical composition comprising remogliflozin and antidiabetic agent. |
| WO2020182792A1 (en) | 2019-03-12 | 2020-09-17 | Dsm Ip Assets B.V. | Coated coacervate capsules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
| CN102711739B (en) * | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | Bilayer tablet |
| RU2596787C2 (en) * | 2010-07-09 | 2016-09-10 | БиЭйчВи ФАРМА, ИНК. | Combined delivery system with immediate/sustained release of medicinal agents with short period of half-life, including for remogliflozin |
-
2018
- 2018-06-07 MX MX2019014687A patent/MX2019014687A/en unknown
- 2018-06-07 KR KR1020197038666A patent/KR20200013719A/en not_active Ceased
- 2018-06-07 BR BR112019026029-3A patent/BR112019026029A2/en not_active IP Right Cessation
- 2018-06-07 CN CN201880038198.9A patent/CN110753540A/en active Pending
- 2018-06-07 PH PH1/2019/502767A patent/PH12019502767A1/en unknown
- 2018-06-07 WO PCT/IB2018/054091 patent/WO2018198102A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN110753540A (en) | 2020-02-04 |
| BR112019026029A2 (en) | 2020-06-23 |
| WO2018198102A1 (en) | 2018-11-01 |
| PH12019502767A1 (en) | 2020-10-26 |
| KR20200013719A (en) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003091A1 (en) | Combination therapy. | |
| CR9737A (en) | DRUG DRUG ADMINISTRATION DEVICES CONTAINING O-DEMETILVENLAFAXIN (ODV) ITS SALTS. | |
| JP2015523407A5 (en) | ||
| AR082091A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PIOGLITAZONA AND LINAGLIPTINE AND PREPARATION PROCEDURE | |
| ECSP066990A (en) | FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO | |
| UY37818A (en) | COMBINATION INCLUDING PALBOCICLIB AND ACID 6- (2,4-DICLOROPHENIL) -5- [4 - [(3S) -1- (3-FLUOROPROPIL) PIRROLIDIN-3-IL] OXIFENIL] -8,9-DIHIDRO-7H- BENZO [7] ANULEN-2-CARBOXYL | |
| ES2916649T1 (en) | Compositions and uses for the treatment of multiple sclerosis | |
| MX2016010179A (en) | COMPOSITIONS OF DONEPEZILO AND METHODS TO TREAT ALZHEIMER'S DISEASE. | |
| DOP2019000070A (en) | AZA-INDAZOLE COMPOUNDS FOR USE IN INJURIES OF TENDONS AND / OR LIGAMENTS | |
| MX385518B (en) | FORMULATION HAVING ENHANCED pH-DEPENDENT DRUG RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS. | |
| AR073265A1 (en) | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK | |
| UY36123A (en) | CARBOXAMIDE DERIVATIVES | |
| CO7250447A2 (en) | Medication form to release active ingredients | |
| AR092356A1 (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN AND METHOD OF PREPARATION OF THE FORMULATION | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| ECSP077843A (en) | PRURITE TREATMENT OR PREVENTION | |
| AR099299A1 (en) | INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| MX2019003362A (en) | Indazole compounds for use in tendon and/or ligament injuries. | |
| CO2018002046A2 (en) | New oral delayed dual dexlansoprazole oral composition | |
| HN2010001775A (en) | ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A SALT OF KETEROLACO AND VITAMINS OF COMPLEX B | |
| MX2021011795A (en) | Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile. | |
| UY37413A (en) | OPROZOMIB IMMEDIATE RELEASE FORMULATIONS | |
| ECSP19024033A (en) | THESOPHENSIN COMPOSITIONS | |
| AR075058A1 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS | |
| PH12020500228A1 (en) | Pharmacutical composition comprising remogliflozin and antidiabetic agent |